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Abstract
Background The phenotypic heterogeneity of circulating tumor cells (CTC) in peripheral blood and disseminated tumor 
cells (DTC) in bone marrow is an important constraint for clinical decision making. Here, we investigated the implications 
of two different subpopulations of these cells in gastric cancer (GC).
Methods GC patients (n = 228) who underwent elective gastric resections were prospectively examined for CTC/DTC. The 
cells obtained from peripheral blood and bone marrow aspirates were sorted by flow cytometry and  CD45− cells expressing 
cytokeratins (8, 18, and 19) and CD44 were identified by immunofluorescent double staining.
Results Ninety-three (41%) patients had cytokeratin-positive tumor cells in either blood or bone marrow, while cells express-
ing CD44 were found in 22 (10%) cases.  CK+CD44+ cells were significantly more common among patients with dis-
tant metastases (50 vs 19%, P = 0.001), while no such correlations were demonstrated for  CK+CD44− cells. Detection of 
 CK+CD44+ cells, but not  CK+CD44−, was associated with significantly shortened survival. Moreover, the Cox proportional 
hazards model identified  CK+CD44+ cells as a negative prognostic factor with an odds ratio of 2.38 (95% CI 1.28–4.41, 
P = 0.006).
Conclusion CD44+ phenotype of cytokeratin-positive cells in blood and bone marrow is an independent prognostic factor 
in patients with gastric cancer.
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Introduction
Gastric cancer (GC) is the third leading cause of cancer 
death worldwide, accounting for nearly 9% of fatalities 
related to human malignancies [1]. Except for some Asian 
countries with effective screening programs, most patients 
are diagnosed with advanced cancers and ultimately die 
from metastatic disease [2]. Therefore, much interest has 
been devoted to the understanding of the mechanisms asso-
ciated with the initiation and progression of the metastatic 
cascade.
Circulating tumor cells (CTCs) in the peripheral blood 
and disseminated tumor cells (DTCs) in the bone marrow 
are a common phenomenon in patients with various malig-
nancies, including gastric cancer [3, 4]. These two pools 
serve as a reservoir for cancer cells detached from the pri-
mary tumor prior to their inoculation to the premetastatic 
niche, and play a crucial role in the formation of distant 
metastases [5]. Detection of CTCs and DTCs offers many 
potential benefits for clinically relevant strategies aimed at 
early diagnosis and monitoring of anti-cancer treatment [6]. 
However, despite numerous efforts to better characterize 
both cell types for clinical decision making, many aspects 
remain controversial.
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A recent meta-analysis of gastric cancer patients sug-
gested that the presence of either CTCs or DTCs was sig-
nificantly associated with impaired disease-free survival 
(HR 3.42, 95% CI 2.39–4.91) while CTCs markedly wors-
ened only the overall survival (HR 2.13, 95% CI 1.13–4.03) 
[7]. However, a considerable degree of heterogeneity was 
observed between individual studies, related to differences 
in population characteristics as well as cell sampling and 
detection methods. Another important aspect of inconclu-
sive results found in some studies could also been caused by 
the phenotypic heterogeneity of CTCs/DTCs, including cell 
clones of varying malignant potential [8–10].
The transmembrane glycoprotein CD44 was one of the 
first molecules identified on gastric cancer stem cells [11]. 
Subsequent studies demonstrated that CD44 in primary 
tumors was associated with a more advanced stage, larger 
tumor size, and more prevalent lymph node metastases [12]. 
Moreover, interactions between the glycoprotein and vari-
ous adhesion molecules, like hyaluronic acid, were found to 
regulate stem cell migration and homing [13, 14]. Therefore, 
it seems reasonable to expect that CTCs/DTCs expressing 
CD44 are potentially more important for disease progression 
that those positive only for cytokeratins.
Our initial observations suggested that cytokeratin-pos-
itive CTCs may have only limited prognostic implications 
[15]. We have also demonstrated that the presence of CTCs 
positive for CD44 was associated with their presence in pri-
mary tumors, but only about 10% of cytokeratin-positive 
CTCs showed expression of CD44 [16, 17]. Taking into 
account the ambiguities related to circulating and dissemi-
nated tumor cells, the purpose of this study was to inves-
tigate the importance of two different phenotypic profiles 
of cancer cells in blood and bone marrow of patients with 
resectable gastric cancer subject to long-term follow-up.
Materials and methods
Patients and treatments
Patients with histologically proven adenocarcinoma of the 
stomach admitted between 2001 and 2007 were prospec-
tively examined for the presence of tumor cells in blood 
and bone marrow. A total of 228 consecutive patients who 
underwent elective gastric resections were selected for this 
study, and the remaining 90 were excluded due to unresect-
able cancers. In general, patients with distant metastases 
identified by preoperative imaging were not qualified for 
surgery. However, if oligometastatic disease limited to the 
peritoneum or liver was found at laparotomy the decision 
about gastric resection was at the discretion of the operat-
ing surgeon.
The extent of surgery was classified as defined by the 
recent guidelines (Japanese Gastric Cancer, 2011). Tumor 
staging followed the seventh edition of the American Joint 
Committee on Cancer classification for gastric cancer [18]. 
All data were prospectively collected and recorded in a dedi-
cated database. Patients were followed by clinical examina-
tions performed every 3–6 months after discharge and dates 
of death were verified by the census registry office. The Bio-
ethics Committee of the Jagiellonian University approved 
the protocol of this study and all patients gave informed 
consent before taking part in the study.
Detection of circulating and disseminated tumor 
cells
Samples of peripheral blood (20 ml) and bone marrow aspi-
rates (5 ml) from the iliac crest were taken before initiating 
any treatment. Pelleted cells were incubated with a lysing 
solution (Becton–Dickinson Biosciences, San Jose, CA) 
for 10 min, repeated 3–4 times to remove erythrocytes. The 
remaining cells were washed in phosphate-buffered saline 
(PBS) and adjusted to the concentration of 1 × 107 cells/ml in 
PBS. Subsequently, the cells were stained with monoclonal 
mouse anti-human CD45 (phycoerythrin labeled) antibodies 
(DAKO, Glostrup, Denmark) and sorted into  CD45+ and 
 CD45− populations using flow cytometry (FACS Vantage 
SE, BD Biosciences) equipped with the TurboSort (BD Bio-
sciences) option and Aerosol Protection System (Flexoduct 
International ApS, Greve, Denmark). The Innova Enterprise 
II ion laser (Coherent, Santa Clara, CA, USA) operating at 
488 nm was used as a light source. Sorting was performed 
using a 70-mm nozzle tip with a drop drive frequency of 
65 kHz, 1.5 drop envelopes and a ‘normal’ sorting mode. 
Sorted  CD45− cells were collected into polystyrene Falcon 
2057 tubes (BD Biosciences, Bedford, MA, USA) precoated 
with fetal calf serum and maintained in a refrigerated bath 
recirculator (Neslab Instruments, Portsmouth, NH, USA). 
About 1 × 106 of  CD45− cells (1 × 106 cells/ml) were used to 
prepare slides. The slides were dried, fixed with a mixture of 
ethanol and acetone (1:1 vol), and then stained for cytokerat-
ins (CK). CK staining was carried out with PE-conjugated 
A45-B/B3 monoclonal antibodies (5 μg/ml) (Micromet 
GmbH, Germany), which recognize common epitopes of CK 
8, 18 and 19. Subsequently, the slides positive for CK were 
double stained with CD44 monoclonal antibodies (G44-26, 
Becton–Dickinson, San Jose, CA) conjugated with fluores-
cein (FITC). The cells were identified by two independent 
investigators under a BX60 fluorescent microscope (Olym-
pus, Tokyo, Japan), including morphological appearance of 
cancer cells, and documented with a DP10 camera (Olym-
pus, Japan). At least 300 cells were examined per slide. The 
samples were regarded as positive when at least 3 cells  CK+ 
per slide were found.
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Statistical analysis
All continuous variables are reported with their median 
and interquartile range (IQR) while categorical data are 
reported as proportions. Statistical significances of the 
differences in categorical and continuous variables were 
analyzed by Chi-square and Mann–Whitney U tests where 
appropriate. Survival data were analyzed according to the 
Kaplan–Meier method and the log-rank test was used to 
detect differences between groups. Multivariate analysis 
was performed using a Cox proportional hazards model 
with a backward stepwise selection procedure. The prob-
ability for entering the model was 0.05 and for removal 
from the model 0.100. All tests were two-sided and 
P < 0.050 was considered statistically significant. Statisti-
cal analysis was performed using the  IBM®  SPSS® Statis-
tics 24 software package (IBM Corporation, NY).
Results
Patient characteristics
There were 151 males and 77 females with a median 
age of 63 years (Table 1). Circulating tumor cells (CTC) 
were found in the peripheral blood of 31 patients, while 
disseminated tumor cells (DTC) were identified in 106 
cases. The median number of CK-positive cells in blood 
or bone marrow was 3 and the same median was found for 
CD44-positive cells in both compartments. Table 2 shows 
the prevalence of CTC and DTC in patients with various 
tumor stages.
Correlation of the presence of CTCs/DTCs 
to clinicopathologic parameters
Table 3 summarizes correlations between the presence of 
CK- and CD44-positive cells in either blood or bone marrow 
and various clinicopathologic parameters. There were no 
significant differences between patients negative for CTC/
DTC and those with CK-positive cells in either compart-
ment. However, cells with CD44 on their surface were about 
twofold more common in patients with distant metastases 
(19 vs 50%, P = 0.001). Moreover, CD44-positive cells were 
more prevalent among poorly differentiated primary tumors 
(73 vs 50%, P = 0.055). When peripheral blood and bone 
marrow were analyzed separately, CD44-positive cells in 
the latter compartment (i.e., DTC) were associated with a 
twofold higher risk of distant metastases (Supplementary 
Tables 1 and 2). M1 disease was also more prevalent among 
cases with CD44-positive cells in blood (CTC), but the 
Table 1  Patient demographics and clinicopathological parameters 
(N = 228)
IQR interquartile range, ECOG Eastern Cooperative Oncology 
Group, AJCC American Joint Committee on Cancer 2010
Age (years) (median, IQR) 63 (53–70)
Male/female, n (%) 151 (66)/77 (34)
ECOG performance status, 0–1/2–3, n (%) 184 (81)/44 (19)
Tumor location, n (%)
 Upper third 42 (18)
 Middle third 41 (18)
 Distal third 121 (53)
 Whole stomach 24 (11)
Primary tumor (T, AJCC 2010), n (%)
 T1 27 (12)
 T2 36 (16)
 T3 100 (44)
 T4 65 (29)
Lymph node metastases (N, AJCC 2010), n (%)
 N0 55 (24)
 N1 23 (10)
 N2 24 (11)
 N3a 53 (23)
 N3b 73 (32)
Distant metastases (M, AJCC 2010), n (%)
 M0 177 (78)
 M1 51 (22)
Tumor stage (AJCC 2010), n (%)
 I 38 (17)
 II 60 (26)
 III 79 (35)
 IV 51 (22)
Type of surgery, n (%)
 Total gastrectomy 150 (66)
 Distal gastrectomy 56 (25)
 Proximal gastrectomy 22 (10)
Residual tumor, n (%)
 R0 130 (57)
 R1/R2 98 (43)
Perioperative chemotherapy, n (%) 132 (58)
Circulating tumor cells, n (%)
 Negative 197 (86)
 CK+CD44− 22 (10)
 CK+CD44+ 9 (4)
Disseminated tumor cells, n (%)
 Negative 122 (53)
 CK+CD44− 91 (40)
 CK+CD44+ 15 (7)
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observed difference was not statistically significant, likely 
due to the small population of patients.
Prognostic implications of CTCs/DTCs
At the time of final follow-up (September 2016), 177 of 
228 patients (78%) had died, and the median follow-up for 
surviving subjects was 99 months (range 76–119 months). 
The overall median survival was 17.3 months (95% CI 
13.1–21.5). A univariate survival analysis with putative 
prognostic factors is illustrated in Table 4. Presence of 
CD44-positive cells in either blood or bone marrow sig-
nificantly shortened median survival (6.7 months) compared 
to patients negative for CTC/DTC (22.3 months) and those 
with CK-positive cells (22.3 months) (Fig. 1). Moreover, 
this effect was still eminent if both compartments were ana-
lyzed separately (Fig. 2). However, CK-positive cells did 
not influence prognosis for DTC and CTC. A proportional 
hazards model constructed with only those variables that 
significantly affected survival in the univariate analysis iden-
tified five independent prognostic factors (Table 5), includ-
ing CD44 positive cells with an odds ratio of 2.38 (95% CI 
1.28–4.41; P = 0.001). Similar results were obtained in the 
population of patients subject to curative R0 resections (Sup-
plementary Table 3).
Discussion
Liquid biopsies to detect circulating and disseminated 
tumor cells offer a unique opportunity to look for poten-
tial biomarkers associated with disease progression. Using 
a well-defined population of patients with resected gastric 
cancer and prospectively observed for at least 6 years we 
have specifically demonstrated that the phenotype of cancer 
cells identified in blood and bone marrow was one of the 
major independent prognostic factors for long-term survival.
Several previous meta-analyses suggested that CTC and 
DTC may have some prognostic importance. One of the 
more recent publications, summarizing data from 26 stud-
ies involving 2566 patients, demonstrated that such tumor 
cells play an important role also for gastric cancer [7]. 
Huang et al. showed that the detection of CTC/DTC sig-
nificantly shortened disease-free survival (HR 3.42, 95% 
Table 2  Prevalence of 
circulating tumor cells and 
disseminated tumor cells 
according to tumor staging
Numbers in parentheses are percentages
Stage Circulating tumor cells Disseminated tumor cells
Negative (n = 197) CK+CD44− 
(n = 22)
CK+CD44+ 
(n = 9)
Negative (n = 122) CK+CD44− 
(n = 91)
CK+CD44+ 
(n = 15)
I 35 (18) 1 (5) 2 (22) 19 (16) 18 (20) 1 (7)
II 51 (26) 8 (36) 1 (11) 36 (30) 22 (24) 2 (13)
III 69 (35) 8 (36) 2 (22) 42 (34) 33 (36) 4 (27)
IV 42 (21) 5 (23) 4 (45) 25 (20) 18 (20) 8 (53)
Table 3  Correlations of clinicopathological parameters with circulating and disseminated tumor cells
IQR interquartile range, CK cytokeratin
*Chi-square test, †Mann–Whitney U test
Parameter CK/CD44 staining P
Negative (n = 113) CK+CD44− (n = 93) CK+CD44+ (n = 22) Negative vs 
 CK+CD44−
Negative vs 
 CK+CD44+
CK+CD44− 
vs 
 CK+CD44+
Age (years) (median, IQR) 65 (55–70) 62 (53–70) 63 (52–69) 0.204† 0.652† 0.757†
Female (n, %) 39 (35) 32 (34) 6 (27) 0.987* 0.510* 0.522*
Tumor grade (n, %) 0.867* 0.055* 0.073*
 Well or moderate
 Poor
56 (50)
57 (50)
45 (48)
48 (52)
6 (27)
16 (73)
Primary tumor (n, %) 0.799* 0.648* 0.553*
 T1–T2
 T3–T4
31 (28)
82 (72)
27 (29)
66 (71)
5 (23)
17 (77)
Metastatic lymph nodes (n, %) 83 (73) 70 (75) 20 (91) 0.766* 0.078* 0.110*
Distant metastases (n, %) 21 (19) 19 (20) 11 (50) 0.738* 0.001* 0.004*
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CI 2.39–4.91), while overall survival was hampered only 
by the presence of CTC (HR 2.13, 95% CI 1.13–4.03). 
Although their results clearly implied impaired prognosis 
due to the presence of cancer cells either in the blood or 
bone marrow, there was a marked heterogeneity among 
studies potentially attributable to the functional heteroge-
neity of these cells [8].
CTCs/DTCs are an important element of the ‘seed and 
soil’ theory explaining the concept of distant metastases 
associated with human malignancies [19]. However, it is 
clear that the functional status of these cells, corresponding 
to the presence of some surface markers, has a major impact 
on the ability to engraft into the preconditioned target niche 
and develop metastatic lesions. Several molecular targets 
Table 4  Univariate analysis of 
prognostic factors
*Log-rank test
ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer 2010, JGCA 
Japanese Gastric Cancer Association, CTC circulating tumor cells in blood, DTC disseminated tumor cells 
in bone marrow
Parameters Category Median survival 
months (95% CI)
Odds ratio (95% CI) P*
Age (years) < 65 20.3 (8.1–32.5) 1.00 0.081
> 65 15.6 (10.8–20.4) 1.30 (0.96–1.75)
Gender male 17.1 (10.3–23.9) 1.00 0.292
female 17.3 (11.5–23.1) 0.84 (0.61–1.16)
ECOG performance status 0 or 1 25.9 (15.1–36.8) 1.00 0.043
2 or 3 13.9 (11.1–16.7) 1.42 (1.01–1.83)
Tumor location whole stomach 8.5 (6.5–10.6) 1.00 0.007
upper third 22.6 (12–33.2) 0.47 (0.27–0.83)
middle third 14.0 (9.9–18.1) 0.67 (0.39–1.15)
distal third 22.3 (11–33.6) 0.46 (0.29–0.75)
Tumor grade G1 32.2 (15.3–49.0) 1.00 0.011
G2 23.0 (11.9–34.2) 1.01 (0.58–1.71)
G3 10.9 (8.3–13.4) 1.62 (0.97–2.69)
Depth of infiltration (AJCC) T1 147.6 (64.3–230.8) 1.00 < 0.001
T2 90.5 (28.8–152.2) 1.28 (0.62–2.64)
T3 24.8 (18.2–32.4) 3.54 (1.92–6.51)
T4 12.8 (8.2–19.4) 8.31 (4.40–15.67)
Lymph node status (AJCC) N0 87.4 (69.9–104.9) 1.00 < 0.001
N1 83.3 (67.2–98.9) 0.95 (0.47–1.92)
N2 28.8 (14.5–43.0) 2.02 (1.12–3.67)
N3a 14.2 (11.7–16.6) 3.45 (2.15–5.52)
N3b 7.9 (5.4–10.5) 6.68 (4.24–10.52)
Distant metastases (AJCC) No 29.7 (13.9–45.5) 1.00 < 0.001
Yes 6.7 (4.8–8.5) 4.86 (3.39–6.96)
Curative resection Yes 54.5 (38.5–70.6) 1.00 < 0.001
No 8.7 (6.6–10.7) 4.09 (2.99–5.59)
Splenectomy No 27.9 (18.1–37.7) 1.00 0.003
Yes 11.7 (8.5–14.9) 1.57 (1.17–2.12)
Lymphadenectomy (JGCA) D1 20.8 (11.2–30.4) 1.00 0.836
D2 17.9 (5.8–30.1) 0.81 (0.35–1.87)
D2+ 17.7 (8.7–26.7) 0.79 (0.33–1.96)
Need for blood transfusion No 25.9 (15.1–36.8) 1.00 0.237
Yes 13.9 (11.1–16.7) 1.12 (0.94–2.36)
Perioperative chemotherapy No 18.2 (6.6–29.8) 1.00 0.116
Yes 15.6 (10.6–20.6) 1.27 (0.94–1.73)
CTC/DTC staining Negative 17.9 (10.5–25.4) 1.00 0.001
CK+CD44− 22.3 (10.1–34.6) 1.00 (0.73–1.38)
CK+CD44+ 6.7 (5.5–7.8) 2.35 (1.46–3.77)
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were previously used to detect CTCs/DTCs in patients with 
gastric cancer, including CEA [20], mucin 1 [21], c-Met 
[22], human telomerase reverse transcriptase (hTERT) [23], 
epithelial cell adhesion molecule (EpCAM) [24], survivin 
[25], and matrix metalloproteinase-1 (MMP-1) [26]. Nev-
ertheless, the ‘gold standard’ of cell surface markers for the 
detection of cancer cells was attributed to cytokeratins (prin-
cipally CK8, CK18 and CK19), playing an important role 
in the cytoskeleton of epithelial tissues [27]. Our method 
combining ‘concentration’ of tumor cells by separating 
 CD45− cells (leukocyte common antigen), IHC detection 
of cytokeratins, and morphological evaluation under a light 
microscope, showed high specificity and the ability to detect 
1 tumor cell per  106–107 leukocytes [17]. However, the pro-
cess of epithelial-to-mesenchymal transition (EMT) required 
for primary cancer cells to acquire new features essential 
for the invasion of distant sites may be associated with loss 
of typical epithelial markers [8, 28]. Thus, cells expressing 
non-CK markers may potentially be more clinically relevant.
The lymphocyte homing receptor CD44 was proposed 
as a marker for cancer stem cells of many solid malignan-
cies, including gastric cancer [29]. In the latter case,  CD44+ 
tumors were associated with an increased risk of death (HR 
1.87, 95% CI 1.55–2.26) as recently demonstrated in a meta-
analysis of 4729 patients [30]. This could be at least partially 
attributed to the highly malignant potential of the subpopu-
lation of  CD44+ gastric cancer cells, as demonstrated by 
patient-derived tumor xenograft models [31, 32]. However, 
the presence of the homing receptor is relevant also for the 
potential tumorigenicity of CTCs. Two independent studies 
demonstrated that  CD44+ CTCs isolated from peripheral 
blood of gastric cancer patients were able to induce tumors 
when injected into immunodeficient mice [33, 34]. Moreo-
ver, the majority of tumors induced in such an experimental 
model showed high expression levels of CD44 [35]. Finally, 
a small study recruiting 45 patients suggested that CTCs 
positive for CD44 were associated with shorter disease-free 
survival compared to CTCs expressing cytokeratin 19 [36].
In the current study, a well-defined population of West-
ern patients with gastric cancer combined with long-term 
follow-up provides a unique opportunity to study the impor-
tance of CTCs/DTCs. A two-step procedure, combining 
sorting out all leukocytes  (CD45+) and searching for cells 
positive for common epitopes of cytokeratins (CK8, CK18 
and CK19) and CD44, demonstrated that it was not the pres-
ence of cancer cells, but their phenotype that determined 
patients’ prognosis. Cells positive for CD44, found either in 
the peripheral blood or bone marrow, were associated with 
a twofold higher risk for distant metastases and mortality. In 
contrast, cytokeratin-positive cells had no major impact on 
clinical outcomes. To our knowledge this is the first large-
scale study that provided clinically relevant data to confirm 
previous experimental observations on the role of CD44 for 
CTCs/DTCs in patients with gastric cancer.
Our results provide an important framework for further 
studies focused on the role of various populations of CTC/
DTC for clinical settings. It seems unlikely that detec-
tion of such cells would be used as an early diagnostic 
Fig. 1  Kaplan–Meier analysis 
of overall survival according 
to the presence of cytokeratin 
(CK) and CD44-positive tumor 
cells in peripheral blood and 
bone marrow (*P, log-rank test)
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biomarker due to the low prevalence of tumor cells in 
either peripheral blood or bone marrow. Hence, it is much 
more reasonable to expect that CTC/DTC could be used 
to monitor response to systemic chemotherapy [37] or 
identify patients who would have more advantage from 
adjuvant treatment after surgery of primary cancer [38]. 
However, some important technical limitations should 
also be considered. Currently, there are several technolo-
gies dedicated to detection of CTC/DTC and no definite 
diagnostic standard has been established so far, even 
though immunocytochemical staining with monoclonal 
antibodies against cytokeratins is commonly accepted as 
an adequate analytical method [27, 39]. Application of 
A45-B/B3 antibodies that recognize common epitopes of 
cytokeratins increases the possibility of detecting tumor 
cells among the  CD45− population of blood and bone mar-
row cells. However, loss of the epithelial markers during 
the epithelial-to-mesenchymal transition poses the risk 
Fig. 2  Kaplan–Meier analysis of 
overall survival according to the 
presence of cytokeratin (CK) 
and CD44-positive tumor cells 
(*P, log-rank test). a peripheral 
blood; b bone marrow
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that some tumor cells could be undetected, thus falsely 
classifying patients as free from CTCs/DTCs. Therefore, 
further studies are urgently needed to account for the het-
erogeneity in the immunohistologic profile of circulating 
and disseminated tumor cells.
In conclusion, the results of this large prospective study 
recruiting Western patients with gastric cancer demonstrated 
that the prognostic relevance of circulating tumor cells in 
blood and disseminated cells in bone marrow is determined 
by their phenotype. Detection of cytokeratin-positive cells in 
either body compartment does not predict poorer prognosis.
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